Abstract:Background: Commonly used glucocorticoids replacement regimens in patients with hypopituitarism have difficulty mimicking physiological cortisol rhythms and are usually accompanied by risks of over-treatment, with adverse effects on glucose metabolism. Disorders associated with glucose metabolism are established risk factors of cardiovascular events, one of the life-threatening ramifications. Aim: To investigate the glycometabolism profile in patients with hypopituitarism receiving prednisone (Pred) replacement, and to clarify the impacts of different Pred doses on glycometabolism and consequent adverse cardiovascular outcomes. Methods: Twenty patients with hypopituitarism receiving Pred replacement [patient group (PG)] and 20 normal controls (NCs) were recruited. A flash glucose monitoring system was used to record continuous glucose levels during the day, which provided information on glucose-target-rate, glucose variability (GV), period glucose level, and hypoglycemia occurrence at certain periods. Islet β-cell function was also assessed. Based on the administered Pred dose per day, the PG was then regrouped into Pred > 5 mg/d and Pred ≤ 5 mg/d subgroups. Comparative analysis was carried out between the PG and NCs. Results: Significantly altered glucose metabolism profiles were identified in the PG. This includes significant reductions in glucose-target-rate and nocturnal glucose level, along with elevations in GV, hypoglycemia occurrence and postprandial glucose level, when compared with those in NCs. Subgroup analysis indicated more significant glucose metabolism impairment in the Pred > 5 mg/d group, including significantly decreased glucose-target-rate and nocturnal glucose level, along with increased GV, hypoglycemia occurrence, and postprandial glucose level. With regard to islet β-cell function, PG showed significant difference in homeostasis model assessment (HOMA)-β compared with that of NCs; a notable difference in HOMA-β was identified in Pred > 5 mg/d group when compared with those of NCs; as for Pred ≤ 5 mg/d group, significant differences were found in HOMA-β, and fasting glucose/insulin ratio when compared with NCs. Conclusion: Our results demonstrated that Pred replacement disrupted glycometabolic homeostasis in patients with hypopituitarism. A Pred dose of > 5 mg/d seemed to cause more adverse effects on glycometabolism than a dose of ≤ 5 mg/d. Comprehensive and accurate evaluation is necessary to consider a suitable Pred replacement regimen, wherein, flash glucose monitoring system is a kind of promising and reliable assessment device. The present data allows us to thoroughly examine our modern treatment standards, especially in difficult cases such as hormonal replacement mimicking delicate natural cycles, in conditions such as diabetes mellitus that are rapidly growing in worldwide prevalence.

Prednisolone-Glucose Derivative Conjugate: Synthesis, Biodistribution and Pharmacodynamics Evaluation

Prednisolone Succinate-Glucosamine Conjugate: Synthesis, Characterization and in Vitro Cellular Uptake by Kidney Cell Lines

Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine

Synthesis and in Vivo Distribution of 2-Deoxy-2-aminodiglucose-prednisolone Conjugate（dpc）

Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.

L-Carnitine ester of prednisolone: pharmacokinetic and pharmacodynamic evaluation of a type I prodrug.

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

[Kidney-Targeting Characteristics of N-acetyl-L-glutamic Prednisolone Prodrug].

Glycyrrhizic Acid-Phospholipid Complex: Preparation Process Optimization and Therapeutic and Pharmacokinetic Evaluation in Rats

Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug

Synthesis, Transport and Mechanism of a Type I Prodrug: L-Carnitine Ester of Prednisolone

Rational Design, Synthesis and Evaluation of γ-CD-Containing Cross-Linked Polyvinyl Alcohol Hydrogel as a Prednisone Delivery Platform

Red blood cell membrane-camouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery

Glucose metabolism profile recorded by flash glucose monitoring system in patients with hypopituitarism during prednisone replacement

Inflammation-targeted Sialic Acid-Dexamethasone Conjugates for Reducing the Side Effects of Glucocorticoids

Glucocorticoids-based Prodrug Design: Current Strategies and Research Progress

Protopanaxadiol synergizes with glucocorticoids to enhance the therapeutic effect in adriamycin-induced nephrotic syndrome

Design and Evaluation of Glomerulus Mesangium-Targeted PEG-PLGA Nanoparticles Loaded with Dexamethasone Acetate

Randomly 50%N-Acetylated Low Molecular Weight Chitosan As a Novel Renal Targeting Carrier

The Investigation of a Prednisolone Prodrug for Colon-Specific Drug Delivery

Renal-specific Delivery of Prednisolone-Folate Conjugates for Renal Ischemia/reperfusion Injury